484
HLAVNÍ42522001005185134178232252
TÉMA69222001003981147194
Sekvenování42533001003773107146180218257293328366381
a822330010034
kombinace87233001003471131170185223257288322
terapií12103300100256085120158174189
při14153300100376179
kardio-reno-metabolickém15103300100336993131146185211235270308347373433468495531569609624639670704738798
syndromu:232433001002865104142166205265303318
GLP-1265833001004475117143164
RA,283833001004287104
SGLT2295833001003682113146182
inhibitory,31563300100145290105143158185224248287298
hypolipidemika347033001003773112151167182220235273309369384418454
a3940330010034
antagonisté39903300100347198135173212250265294321356
mineralokortikoidních436233001005974112148172207223262296334358387404438476491529567582612650
receptorů50283300100235889123161187226251289
38819222001003476118
|350220010018
VNITŘNÍ4268040010746106127172220280301
LÉKAŘSTVÍ748804001074185130188236280325378400
/11948040010731
Vnitř1270804001074693112140166
Lék.1456804001074083122140
2026;72(6):388-3941615804001074487129171186227271292334356371415459504532573615660
/23208040010731
www.casopisvnitrnilekarstvi.cz442680400107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
https://doi.org/10.36290/vnl.2026.07242544001003865941331631802022236484400100418310274944001001554791171398904400100287389124167204247293316355396414432470516552594611655686724
Sekvenování4259800275115234362492607735861983110312311297
a17999800275116
kombinace196298002751222444315606257538749751092
terapií3131980027585202295414543608674
při38829800275123216282
kardioreno-metabolickém424198002751212423354635296554251240027587206334460560747866956107912081333139914651566169318081996
syndromu:2498124002759822635448357570188810161085
GLP-1366012400275131243381475591
RA,432812400275137290365
SGLT242515000275115252363475608
inhibitory,1110150002756018831638251157666679088310151075
hypolipidemika22621500027512224937750356963576382995710761263132914561577
a391615000275116
antagonisté407915000275116244334456585711839904100910971214
mineralokortikoidních425176002751822473754945877067728981024114712391332139915251648171318421969203621362264
receptorů27661760027587206307424553644769861988
Michal4252150013793124174239297327
Dubský7752150013776141207255315376
Centrum4252300013364117178213248309400
diabetologie,848230001336287140201257293352378439501526580602
Institut1473230001332687129166191227287323
klinické1819230001335279104164189238288342
a21842300013353
experimentální22602300013355107169225261286377432493528582607667692
medicíny,29752300013392147210235284308369418435
Praha3434230001335893146206258
Kardio-reno-metabolický425281001215410513919622127731234739845551154663268471876982788490993397910271078
(KRM)1534281001212883139221249
syndrom1814281001213989147205238294379
–22242810012150
v23042810012149
anglické23832810012149105163187211257305355
literatuře276928100121234882132167216250306340391
označovaný3191281001215598155204250305353403460507
jako3728281001212474122177
CKM39352810012158113197
(cardiovascular-kidney-metabolic)416228100121297212215521323729434239243247953555960964267172174780586191396199310791131116612161274133142529500121244893121
–5742950012150
je651295001212576
koncept7542950012147102159205255313347
zavedený1128295001214394142192250301358404
konsenzem15602950012147102158198250306350401486
Americké20742950012161145196230255301348398
kardiologické2499295001214798131188212268293350407432477525575
asociace3101295001214888145191215264310360
(AHA)3488295001212990156217246
v37612950012149
roce3837295001213388135185
2023.40492950012152103152204225
Popisuje43022950012153107165190230286310362
propojený4691295001215791146205261286338394441
komplex51592950012147102186244269321369
obezity,4253090012155113165209234268319336
diabetes787309001215681129187239274324364
mellitus11783090012183135160184208242298338
2.1542309001215174
typu1642309001213384143199
(DM2T),1867309001212995177228279311330
dyslipidemie,22233090012157106146170194252277334385470494545566
chronického28163090012144100134189246270316364413470526
onemocnění33693090012155111163247303350406458514538
ledvin3934309001212374133182207263
(CKD4223309001212986140208
–44583090012150
chronic45343090012145101134190247271317
kidney4877309001214773130186238286
disease)5189309001215680120172221261313339
a4253230012149
kardiovaskulárního504323001214798132190214271319369410458515539589623680705763820
(KV)1355323001212883144176
onemocnění15623230012155112164250306353410462519544
včetně2136323001214994144179236288
srdečního2454323001214074131183230287311370427
selhání2911323001214092117174223280305
(HF).3246323001212995145175195
Současná34723230012149106163209259300356406
evidence39083230012151100125183235292339389
z43283230012143
velkých4402323001214899124172224269326
randomizovaných4758323001213383140198255340365409465514564620667713769
studií425337001214074130188212236
podporuje6853370012157114172230287321377402453
časné1162337001214594134191242
sekvenování1428337001213991139191241298354402452508532
a19843370012148
u20563370012155
vhodně21353370012148105161219275327
vybraných2486337001214899158192241298344389445
pacientů29553370012157106152176227284317373
kombinaci33523370012147102186244269325374420444
několika38193370012156107155210235259307357
terapeutických4200337001213383117166224276332367391436484535580636
tříd486033700121336691148
–50323370012150
inhibitorů5106337001212379136160217242276331365421
SGLT2,4253510012149113161204257278
agonistů7223510012148104159215239278312367
receptoru1108351001213383129178235268323356411
pro1539351001215689144
GLP-117023510012164112165195241
(GLP-11962351001212890138191221267
RA),22483510012153117144164
hypolipidemik24313510012155100158214239262319343400450534557604
(statiny,3054351001212866100149182206261307323
ezetimib,3396351001215094144178201284308364384
inhibitory3800351001212378134157214238271326359409
PCSK9,42293510012152110160214266284
inklisiran,4532351001212378125151174214237270318374395
kyselina4946351001214797137188212236291339
bempedová)530435100121571081914253650012157109167223272321348
a7983650012148
nesteroidního8713650012155107147182232266322346404460484543599
antagonisty14943650012148105138188245301358382422457508
mineralokortikoidních20263650012184108164215249299323379428482516553577625680704762818842888944
receptorů2994365001213384131181239273328362418
finerenonu.3437365001212956112164197248305361418473495
Přínos3957365001215386110167223263
těchto4245365001213383129186219274
tříd454336500121346791149
je4716365001212576
v48173650012148
řadě4889365001213382140191
klinických510536500121477397153177223270322366422
scénářů425379001214086136192241275331
komplementární,7813790012147101186244269320405456513546596630686710732
zatímco1538379001214394127151235282336
důkaz18993790012156112160210254
přímé2178379001215791115199251
aditivity24543790012148106130164188237262296347
všech2826379001214888140186242
kombinací30933790012147102186244269325374420444
zůstává3562379001214298139173223271320
omezený.39073790012155140191235286343390407
Data43393790012166115149199
ze4562379001214394
studie4681379001214074130188212263
CONFIDENCE49693790012158125192242265333384450509558
podporují4253930012157114172230287321377402426
bezpečnost8763930012157109153211263310366422462497
a13983930012149
albuminurický1472393001214872130186270295351407440465510558609
efekt2106393001215081133181218
současného2349393001213996152198247288344395452508
zahájení2882393001214394150199224275332356
finerenonu3263393001212957113164198249306362418474
a37623930012148
empagliflozinu;38363930012150134192242299323347377405461504528584640661
dopad45223930012156112170220278
na48253930012155104
tvrdé4955393001213384119176227
klinické520739300121477397153178223271321
endpointy4254070012150107164222279303360393444
však894407001214888138186
vyžaduje11044070012148100146197254310335386
další15154070012156105130170194
data.17344070012156105139189211
Tento1970407001214994151184239
přehledový2234407001215791141198223274332388437488
článek2747407001214569118174225274
shrnuje3045407001214096130187242267318
patofyziologii33884070012157107140195225277323348404429485543567591
KRM,40044070012154110192215
evidenci4244407001215098123181232289335359
pro4628407001215690146
jednotlivé4799407001212475134190246280304328377428
lékové5251407001212475124178226276
třídy42542100121336791148197
a6444210012148
praktický715421001215791140188225249295342393
algoritmus1131421001214872130186220244278362418458
jejich1612421001212476100125170226
kombinace.18614210012147101186244269325374420470491
Pozornost23744210012153107150206240297353393428
je2824421001212576
věnována2922421001214898155211259309365414
nově33584210012156112160210
publikovaným35904210012157114172197221268323371421477523608
americkým42214210012148132184218242288335387472
doporučením47154210012157113171228262318364414471495579
ACC/53164210012162118174211
AHA4254350012161127189
20266374350012151102152202
pro862435001215791147
léčbu1032435001212475122179235
dyslipidemie12914350012156105145169193251276333384469493544
ve1859435001214898
srovnání1980435001214073129177234283339363
s23664350012140
evropským2429435001215099133189247287335386471
updatem29244350012155112171220253304388
ESC/EAS33354350012150100159196247310362
202537204350012151102152204
a39474350012148
draftu4018435001215790140170207263
KDIGO43044350012155123149215284
2026.46124350012151102152202224
Klíčová425452001235986112157213264315
slova:768452001234268125176227250
dyslipidemie,10474520012157105145168192249273330381465488539559
finerenon,1635452001212956111162195246302358414435
GLP-120984520012166114167197243
receptoroví2369452001213384130179237270325358413461485
agonisté,28824520012149105161217241280314364384
inklisiran,3295452001212379126152175214238270319375396
inhibitory3720452001212379135158215239273327361411
PCSK9,41604520012154112162216268286
kardio-reno-metabolický447545200121479612918620926529933338343949552961466569974880586288690995410011052
syndrom,425466001214088144201233288371392
SGLT28384660012150114162205257
inhibitory,1117466001212378134157213237270324357407423
sekvenování1562466001213990137188237293348395443499522
terapie.2105466001213382115164220244294314
Sequencing4254910015063126195263327395449483552620
and10844910015063131200
combination13234910015052118219287321390454502537604672
of20334910015066114
therapies21864910015046115178227291359394456512
in27364910015033102
the28764910015046115178
cardiovascular-kidney-metabolic3093491001505211716623426933640146552057464267674179184291094510141082114512121262136214261474153916081675170917441797
syndrome:49284910015054122191259308376476539575
GLP-14255050015072131205255317
RA,7805050015075157196
SGLT210155050015062135195254325
inhibitors,13795050015033101169204273307354421470525562
lipid-lowering1980505001503267136170238290325392484545595629697766
drugs27845050015067116184252308
and31305050015064132201
mineralocorticoid33695050015099134202265315378412480533600648698733786852886955
receptor43625050015048111165227296344411460
antagonists48605050015064132179245313381449483539585641
Cardiovascular-kidney-metabolic4255250012158106138194217272319367406451505529576609636684709765820870917948103210821115116412211276130013231367
(CKM)1810525001212884137219245
syndrome2073525001213987143200232286370420
is2511525001212362
a25915250012148
concept2656525001214599154199248304337
introduced3011525001212378110143197254308353402459
by34885250012157103
the3608525001213388139
202337645250012151101150200
consensus3982525001214598154193243298337391430
statement4430525001213973122154203286336392424
of4872525001215583
the4973525001213388138
American51295250012161144194227250295343398
Heart4255390012165116164197232
Association6815390012162102141197242265313346369424479
(AHA).1184539001212989154214242260
It1468539001212457
describes15495390012156107146191224247304355394
an19675390012148104
interconnected2095539001212378111160193237291346402452498533582640
complex2758539001214599183239263314361
of3143539001215584
obesity,32515390012155112163202225258308324
type3599539001213383141192
238155390012151
diabetes3890539001215679127184235268318357
mellitus42715390012183134158181204237292331
(T2DM),4626539001212881133199279306325
dyslipidemia,49745390012157105144167190247271327377461484532553
chronic4255530012145100132187243266310
kidney758553001214772128183234281
disease1061553001215680119169217256307
(CKD),1390553001212984137205231250
and16625530012149104160
cardiovascular1845553001214593126182205260307356395440495518566599
(CV)2466553001212984143174
disease,2662553001215780119169217256307327
including3011553001212479124147202258281337393
heart34265530012156106154187223
failure3671553001212978101125179212262
(HF).3955553001212892141170189
Current41665530012158111144177227282315
evidence4503553001215098122178228284329378
from4903553001213063118201
large5127553001212371104160210
randomized53595530012133811374255670012156111195218261311368
trials81156700121336589136160199
supports1028567001213993150207263296331372
early1418567001215098130154201
sequencing1637567001214090147202252308352375430486
and,21415670012148104160181
in2340567001212378
appropriately24365670012148105162195249306339363410443492516563
selected3017567001214090114164210245294351
patients,33865670012157106138161211267299339360
combination3764567001214599182239262317365398421476531
of4313567001215584
several4415567001213990137186219267291
therapeutic4724567001213388138171219276327382415438483
classes:5224567001214568116155194245284304
SGLT24255810012149114161204257
inhibitors,706581001212378133157213237270324357397418
glucagon-like1148581001215679134179227283339394426451474521570
peptide-117415810012157108165198222278328362407
receptor2171581001213383129178235268322355
agonists25495810012149104160215238277311352
(GLP-12924581001212991139192221267
RAs),32145810012154117158183201
lipid-lowering3439581001212346103127183215240295368417450474529585
therapies4048581001213388138171220276300350390
(statins,4461581001212966100149181204259298320
ezetimibe,4804581001215093143177200283306363414434
PCSK952615810012153111161215266
inhibitors,425595001212379134157214237270324357398419
inclisiran,864595001212479124147170209232264313368389
bempedoic12735950012157108192248299357412435480
acid),1773595001214993116173201220
and20135950012148104160
the2194595001213388138
nonsteroidal23535950012155110166205239288321376399456504527
mineralocorticoid29015950012183106161212245293317372417471504540563608661685741
receptor3663595001213282128177234267321354
antagonist40375950012149104136185241296352375414448
finerenone.4505595001213056111161194244300355411461481
The50075950012149106156
benefits51835950012157108164214244270303344
of425609001215584
these531609001213389139178229
drug782609001215789145201
classes1005609001214568116155194245284
are1311609001214981131
complementary1464609001214599182239263313397448503536584617667
in2153609001212479
several2254609001214090138187220268292
clinical256860900121456891146169214263286
scenarios,2877609001213984133189237269293348387408
whereas33086090012173129180212262310349
direct3680609001215679112162207242
evidence3945609001215097121178228284329378
for4345609001212984117
additive44856090012148105161184217240289338
effects4845609001215080113163209244285
across5152609001214893125180219258
all543360900121487194
combinations425623001214599182239263318366398421476532571
remains1022623001213382166214237292331
limited.1379623001212447130153186235293314
Data17186230012167115147196
from1940623001212963117201
the2167623001213388138
CONFIDENCE23316230012158124190239261328378443501549
trial290662300121336689137161
support3092623001214094151208264297333
the3451623001213388138
safety3615623001214089118168202251
and38926230012148104160
albuminuria-lowering4078623001214872128184267290345400432456504536561616689738771795850906
effect5010623001215080112163208244
of5279623001215584
the5389623001213388139
simultaneous425637001214062146200224257306361411467522562
initiation1008637001212379102135158206238261316372
of1401637001215584
finerenone1507637001212955110161194244299354410460
and19896370012148103160
empagliflozin;21706370012150134191239295319342371397453494518573592
however,27846370012155110183233280329362378
its318463700121235697
impact33026370012124107163212257292
on36166370012154110
hard37486370012155103136192
clinical396163700121456891146169214263286
endpoints42696370012150105162219275298353386426
requires4717637001213282139194217250299339
further5077637001212985118154209259292
data.53916370012156104425651001213382103
This5506510012150106129168
review740651001213383130154204277
summarizes1039651001214094178261309341365408458497
the1558651001213388139
pathophysiology17186510012157106139194249306362407447470525549604661709
of2448651001215584
CKM25546510012158111194
syndrome,2770651001213987144200233287371422441
the3233651001213388139
evidence3394651001215097121178228284329378
for3794651001212984117
individual3933651001212378135158206230287341389413
drug4368651001215689144200
classes,4590651001214568116155194245284305
and49176510012148103160
a50996510012148
practical5169651001215790138183218241286335358
algorithm425665001214872128183216239273328411
for863665001213085118
their1008665001213388139162195
combination.1230665001214599182239263318366399422477532553
Particular18116650012153100133169192237291315363395
attention2234665001214881116165221253276331387
is2649665001212362
paid27396650012157105128185
to2952665001213387
the3066665001213389139
newly32336650012155106179203250
published35116650012157112169193216255310361418
202639576650012151101150199
ACC/AHA41846650012161116171207263328389
U.S.4600665001216583135156
guidelines47846650012156111134190241265288343393433
for5244665001213085118
the5389665001213388139
treatment425679001213366115164196279330385418
of864679001215584
dyslipidemia9696790012157104144167190247270327377461484532
in1522679001212379
comparison1622679001214598182239287320343383438493
with2137679001217397130185
the2343679001213389139
202525036790012152102150201
ESC/EAS2725679001215099157193243305356
European31026790012149103135190247298346401
update35246790012155112170218250299
and38456790012148103160
the4026679001213388139
KDIGO41866790012154122146211280
202644876790012151102150200
draft.4708679001215689137166203224
doc.42574000954487124139
MUDr.581740009562112164189200
Michal79974000956279115158195212
Dubský,102974000955195139169203242252
Ph.D.,12997400095408297150163177
FRSPH,149374000953777115155204219
MBA,1729740009562103150165
LL.M19127400095367287152
Centrum42575200954684127151175219284
diabetologie,7277520095436097141181206248266309354371410424
Institut11687520095176090116133158201227
klinické14127520095345369112129165199238
a1667752009537
experimentální172175200953975119160184201267306349374411428471488
medicíny,2226752009566105150167203220263298309
Praha255275200954064101144181
mids@ikem.cz42576400956682126156214232266304370385421456
Cit.43817400095466388103
zkr:45017400095336792108
Vnitř462674000954183100125149
Lék.479374000953674109125
2026;72(6):388-394493674000953977114152166203242261299319332372411451477514551592
Článek45267520095466399142182216
přijat47597520095456986103139164
redakcí:494075200952462107144178213230243
15.52017520095397386
5.530575200953952
2026537575200953977114152
Článek43337640095466399142182216
přijat45667640095456986103139164
po474776400954488
recenzích:48537640095246299137180214231267310323
30.51947640095397892
6.530476400953953
2026537576400953978115153